InsidersTradesSigma
Total declarations
Company
▲ Purchases (7 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
7
Disclosed sells
0
T+90 hit rate
80%
T+90 mean return
+3.1%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Gilmartin Kathleen A, Director. Officer active across 1 company, notably U S Physical Therapy INC /nv. Cumulatively, 12 reports have been logged. Breakdown: 7 buys · 0 sell. Total volume traded: €787k. Activity tracked since 17 May 2021. The latest transaction was disclosed on 20 November 2025 (Acquisition). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Gilmartin Kathleen A
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations12 total
4,000 shares@ US$69.0030.4% of flowCommon StockSEC:0001193125-25-293697:0
Canonical exit: 18 Feb 2026 (T+90)
1,882 shares0Common StockSEC:0000950170-25-075778:0
2,000 shares@ US$86.0921.4% of flowCommon StockSEC:0000950170-24-103046:0
Canonical exit: 2 Dec 2024 (T+90)
1,424 shares0Common StockSEC:0000950170-24-063172:0
1,000 shares@ US$82.3410.6% of flowCommon StockSEC:0001209191-23-055080:0
Canonical exit: 8 Feb 2024 (T+90)
1,600 shares0Common StockSEC:0001209191-23-030619:0
1,000 shares@ US$81.7111.3% of flowCommon StockSEC:0001209191-22-047678:0
Canonical exit: 22 Nov 2022 (T+90)
600 shares@ US$92.267.5% of flowCommon StockSEC:0001209191-22-044937:0
Canonical exit: 6 Nov 2022 (T+90)
1,600 shares0Common StockSEC:0001209191-22-030040:0
1,000 shares@ US$94.2110.6% of flowCommon StockSEC:0001209191-21-068491:0
Canonical exit: 6 Mar 2022 (T+90)
1,000 shares@ US$116.6712.1% of flowCommon StockSEC:0001209191-21-034778:0
Canonical exit: 18 Aug 2021 (T+90)
1,480 shares0Common StockSEC:0001209191-21-033889:0
12 of 12 declarations
About Gilmartin Kathleen A
Kathleen A. Gilmartin is a Board Member at U S Physical Therapy Inc. In this role, she contributes to the governance of the company and strategic decision-making. Her experience in the healthcare sector is valuable in guiding the company in its growth initiatives.
